BIOGEN CELIA
In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD.
The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on what dose of BIIB080 slows worsening of AD the most.
Inclusion Criteria:
- 50 years to 8o years
- Mild Cognitive Impairment or Alzheimer’s Disease
- Availability of a designated study partner (full criteria in link below)
What to Expect
- Participants will receive either a low dose or high dose of BIIB080 or a placebo as an injection into the fluid around the spinal cord. A placebo looks like the study drug but contains no real medicine
For more information click the link below or contact Heather MacNamara at hmacnamara@dentinstitute.com or 716-819-4117
Subscribe To Our Newsletter
Sign up to receive email updates on announcements, new services added, company updates & more!
Want to participate in a study?
Fill out the form below and one of our Research Coordinators will be in contact with you as soon as possible. If we currently do not have a study that is currently available for you, we will add you to our database for future studies.